| Name | Title | Contact Details |
|---|
9to5 Seating is a vertically-integrated, privately owned company, founded in 1986, which specializes in the design and production of ergonomic office seating to accommodate the rigorous demands of todays office environments. 9to5 Seating presents an extensive collection of executive, task, guest, conference, stool and lounge seating. Customization is an everyday demand that 9to5 Seating welcomes; seats, controls, arms, chair adjustments, finishes, and upholstery options are plentiful. 9to5 Seating combines its state-of-the-art, in-house manufacturing systems with a commitment to continuous improvements in all phases of the operation. With over 500,000 sq. ft. of manufacturing resources, we are confidently empowered to deliver products offered at unparalleled pricing, with quality built into every phase of manufacturing. Our dedication to becoming the leader in office furniture requires that we go beyond customer expectations. We strive to provide quality products, plethora of upholstery options, express shipping superior customer service and the best warranty as possible.
Weekes Forest Products, Inc. (WEEKES) is a St. Paul, Minnesota based wholesaler and distributor of wood products and building materials. Founded in 1978, WEEKES has grown to become one of the most successful independently-owned distributors in the United States. Financial Data. WEEKES has earned a reputation as a highly entrepreneurial, sales-driven company with a history of financial success. WEEKES has 8 regional locations. Seven of these enterprises were the result of acquisitions WEEKES has completed since 1986. In the United States, many local and regional distribution companies could add to WEEKES growth. The Company plans to grow internally as well as through future acquisition(s). WEEKES FOREST PRODUCTS LOCATIONS Fargo, ND 800-548-2479 St. Paul, MN 800-328-2890 Green Bay, WI 800-236-6314 Milwaukee, WI 800-222-4698 Chicago, IL 800-398-8266 Grand Rapids, MI 800-442-8082 Tampa, FL-Logan Lumber Co. 800-365-5545 Corporate Culture. WEEKES is an informal, value-driven company where honesty, straight communication, and mutual respect are important. Teamwork, good product knowledge, strong work ethic and cost control are keys to the success of the company.
Based in North Carolina, the partnership of UNX and Christeyns brings together more than 100 years of experience in the textile care industry. Specializing in commercial quality cleaning chemicals for the laundry, housekeeping, warewashing, and dry and wet cleaning markets, these products are supported with custom designed dispensing equipment to produce high efficiency results for customers. Learn more by calling 800-869-6171 for more information or by visiting our website.
For over forty years, Allen & Withrow has maintained a reputation for excellence serving the legal needs of business clients nationwide. Allen & Withrow focuses on Collection Issues for lenders and other businesses. Our seasoned trial attorneys handle collection cases with efficiency, speed, and persistence combined with experience in locating assets and defeating fraudulent conveyances.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.